Welcome to our dedicated page for Absci SEC filings (Ticker: ABSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Absci Corporation filings document a Nasdaq-listed clinical-stage biotechnology issuer developing generative AI-designed biologic therapeutics. Its 8-K reports furnish quarterly and annual financial results, business presentations, and internal pipeline updates for programs such as ABS-201 and the broader prolactin and PRLR portfolio.
Proxy and material-event filings cover board and shareholder matters, executive compensation and equity-plan governance, director and officer indemnification agreements, common stock registered on the Nasdaq Global Select Market, and amendments to material agreements related to prior corporate transactions.
Absci Corporation reported a net loss of $29.6 million for the three months ended March 31, 2026, as it continues to invest in its AI‑driven antibody pipeline. Partner program revenue was $0.2 million, down sharply from $1.2 million a year earlier due to milestone timing and program mix.
Research and development expenses rose to $19.3 million, reflecting higher external preclinical and clinical spending on lead candidate ABS-201 and broader platform work. Selling, general and administrative costs edged down to $9.1 million, while depreciation and amortization fell to $2.7 million as certain lab equipment was retired.
Cash, cash equivalents and marketable securities totaled $125.7 million as of March 31, 2026, against an accumulated deficit of $654.4 million. The company raised $8.0 million in net proceeds via its at‑the‑market equity program and continues to expect significant ongoing spending on clinical development and its Integrated Drug Creation platform.
Absci Corporation reported first quarter 2026 financial and operating results and highlighted progress in its ABS-201 prolactin receptor programs. Revenue was $0.2 million for the quarter, down from $1.2 million a year earlier, while net loss widened to $29.6 million from $26.3 million.
Research and development expenses rose to $19.3 million, mainly to advance ABS-201 and other internal programs, while selling, general, and administrative costs eased slightly to $9.1 million. Cash, cash equivalents, and marketable securities totaled $125.7 million as of March 31, 2026, which the company believes will fund operations into the first half of 2028.
Clinically, Absci completed all four single-ascending-dose cohorts and began dosing the first multiple-ascending-dose cohort in its Phase 1/2a HEADLINE trial of ABS-201 for androgenetic alopecia, with preliminary safety, tolerability, and pharmacokinetic data expected in the second quarter of 2026. The company also introduced ABS-202, an anti-PRLR antibody for an undisclosed inflammation and immunology indication, and outlined plans to initiate a Phase 2 study of ABS-201 in endometriosis in the fourth quarter of 2026.
Absci Corporation presents its Annual Report on Form 10-K describing its AI-native Integrated Drug Creation platform and clinical-stage pipeline focused on antibody therapeutics. The company reports an internally developed lead candidate, ABS-201, in a Phase 1/2a HEADLINE trial and outlines pipeline strategy, IP estate, and regulatory pathways.
Absci says it advanced its first two internal programs from AI design to IND in ~two years at ~$15 million per program. ABS-201 targets the prolactin receptor (PRLR) for androgenetic alopecia and endometriosis; interim proof-of-concept data for AGA are expected in 2H 2026, and a Phase 2 endometriosis study is planned for Q4 2026 subject to data and regulatory review. The company discloses $303.8 million aggregate market value of non-affiliate equity as of June 30, 2025 and 153,021,263 shares outstanding as of March 6, 2026.
Absci Corporation has released its 2026 proxy statement, combining a business update with details for a virtual annual meeting on June 4, 2026. The company highlights ABS-201, an AI-designed antibody that moved from discovery to clinic in about two years at roughly $15 million, versus an industry norm of 4–6 years and more than $50 million. A Phase 1/2a trial for androgenetic alopecia is underway, with clinical proof-of-concept data expected in the second half of 2026, and a global Phase 2 trial in endometriosis targeted for initiation in the fourth quarter of 2026. Absci also introduces its Origin-1 AI model to drive internal pipeline programs and selected partnerships. Stockholders will vote on electing two Class II directors and ratifying Ernst & Young LLP as auditor. The board remains majority independent, and non-employee director cash retainers and equity awards increase under a refreshed 2026 compensation policy.
Absci Corporation major holder Redmile Group, LLC filed an amended Schedule 13D reporting a reduced position in the company’s common stock. The Redmile funds now beneficially own 7,607,449 shares, representing 4.9% of Absci’s common stock, based on 153,021,263 shares outstanding as of March 6, 2026.
On April 10, 2026, Redmile sold 645,867 Absci shares in open market transactions at a weighted average price of $2.979 per share, with individual trades ranging from $2.90 to $3.04. As a result, each reporting person ceased to be a 5% beneficial owner as of that date, while retaining shared voting and dispositive power over the remaining shares.
Absci Corporation’s major shareholder Redmile Group, LLC and Jeremy C. Green have updated their ownership disclosure. They report beneficial ownership of 8,253,316 shares of Absci common stock, representing 5.4% of the outstanding shares, based on 153,021,263 shares outstanding as of March 6, 2026.
The filing explains that their percentage ownership decreased primarily because Absci’s total outstanding common stock increased, rather than from significant share sales. Redmile-managed funds hold the shares directly, while Redmile and Green share voting and investment power and each disclaim beneficial ownership beyond their economic interest.
Absci Corp amendment to a Schedule 13G/A shows The Vanguard Group reports zero shares beneficially owned and 0% of Absci Corp common stock following an internal realignment. The filing clarifies that certain Vanguard subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538.
Absci Corporation outlines its AI-native biopharmaceutical strategy and growing pipeline in its annual report, highlighting progress on antibody programs built with its Integrated Drug Creation platform.
Lead candidate ABS-201, an anti-PRLR antibody, is in the HEADLINE™ Phase 1/2a trial for androgenetic alopecia, with early cohorts dosed and interim safety and exploratory efficacy data expected in 2026 and full proof-of-concept in 2027. The same drug is being advanced toward a planned Phase 2 trial in endometriosis in late 2026.
The company describes its Origin‑1 generative AI system for de novo antibody design, a lab-in-the-loop validation engine, and a business model that blends internally developed programs with partnerships. Absci also notes significant ongoing losses, the need for additional capital, heavy reliance on its platform’s technical success, and intense competition in AI-enabled biologic drug discovery.
Absci Corporation outlines its AI-native biopharmaceutical strategy and growing pipeline in its annual report, highlighting progress on antibody programs built with its Integrated Drug Creation platform.
Lead candidate ABS-201, an anti-PRLR antibody, is in the HEADLINE™ Phase 1/2a trial for androgenetic alopecia, with early cohorts dosed and interim safety and exploratory efficacy data expected in 2026 and full proof-of-concept in 2027. The same drug is being advanced toward a planned Phase 2 trial in endometriosis in late 2026.
The company describes its Origin‑1 generative AI system for de novo antibody design, a lab-in-the-loop validation engine, and a business model that blends internally developed programs with partnerships. Absci also notes significant ongoing losses, the need for additional capital, heavy reliance on its platform’s technical success, and intense competition in AI-enabled biologic drug discovery.
Absci Corporation reported 2025 results showing a widening loss as it invested heavily in its AI-driven drug pipeline while advancing lead program ABS-201. Revenue was $2.8 million for 2025, down from $4.5 million in 2024, reflecting lower partner program revenue.
Research and development expenses rose to $81.4 million from $63.9 million, driving a full-year net loss of $115.2 million versus $103.1 million a year earlier. Fourth-quarter net loss was $29.6 million. A $5.1 million gain from settling contingent consideration added $8.7 million of unrestricted cash.
The company highlighted clinical progress for ABS-201 in androgenetic alopecia, having dosed the first three cohorts in the Phase 1/2a HEADLINE trial with favorable emerging safety data and human ex vivo hair-growth findings. It also plans a Phase 2 trial of ABS-201 in endometriosis in the fourth quarter of 2026 and continues partnering efforts around ABS-101 and other AI-designed antibodies.
Cash, cash equivalents, and marketable securities totaled $144.3 million as of December 31, 2025, compared with $152.5 million as of September 30, 2025. Absci believes this liquidity will fund operations into the first half of 2028, supporting its multi-program clinical and discovery agenda.
Absci Corporation reported 2025 results showing a widening loss as it invested heavily in its AI-driven drug pipeline while advancing lead program ABS-201. Revenue was $2.8 million for 2025, down from $4.5 million in 2024, reflecting lower partner program revenue.
Research and development expenses rose to $81.4 million from $63.9 million, driving a full-year net loss of $115.2 million versus $103.1 million a year earlier. Fourth-quarter net loss was $29.6 million. A $5.1 million gain from settling contingent consideration added $8.7 million of unrestricted cash.
The company highlighted clinical progress for ABS-201 in androgenetic alopecia, having dosed the first three cohorts in the Phase 1/2a HEADLINE trial with favorable emerging safety data and human ex vivo hair-growth findings. It also plans a Phase 2 trial of ABS-201 in endometriosis in the fourth quarter of 2026 and continues partnering efforts around ABS-101 and other AI-designed antibodies.
Cash, cash equivalents, and marketable securities totaled $144.3 million as of December 31, 2025, compared with $152.5 million as of September 30, 2025. Absci believes this liquidity will fund operations into the first half of 2028, supporting its multi-program clinical and discovery agenda.
Absci Corp Chief Legal Officer Shelby J. Walker reported compensation-related equity awards and tax withholding transactions. On March 2, 2026, Walker received 90,300 shares of Common Stock in the form of Restricted Stock Units under the 2021 plan, which will vest in three substantially equal annual installments starting on March 1, 2027, subject to continued service. On the same date, Walker was granted a stock option for 356,300 shares of Common Stock at an exercise price of $2.80 per share, also vesting in three substantially equal annual installments beginning on March 1, 2027. On March 3, 2026, 9,825 shares of Common Stock were withheld by Absci to cover tax obligations from RSU vesting, which the filing states was not a discretionary trade. Following these transactions, Walker directly owned 139,775 shares of Common Stock.